For example, the nonselective phosphodiesterase inhibitor pentoxifylline has been shown to reduce steatosis and fibrosis in MASLD patients [84]; this activity may be mediated through PDE3B inhibition. The gene discussed is PDE3B; the disease is metabolic dysfunction-associated steatotic liver disease.